TY - JOUR
T1 - Design, synthesis, and biological evaluation of 3-(1H-1,2,3-triazol-1-yl) benzamide derivatives as potent pan Bcr-Abl inhibitors including the threonine315←isoleucine315 mutant
AU - Li, Yupeng
AU - Shen, Mengjie
AU - Zhang, Zhang
AU - Luo, Jinfeng
AU - Pan, Xiaofen
AU - Lu, Xiaoyun
AU - Long, Huoyou
AU - Wen, Donghai
AU - Zhang, Fengxiang
AU - Leng, Fang
AU - Li, Yingjun
AU - Tu, Zhengchao
AU - Ren, Xiaomei
AU - Ding, Ke
PY - 2012/11/26
Y1 - 2012/11/26
N2 - A series of 3-(1H-1,2,3-triazol-1-yl)benzamide derivatives were designed and synthesized as new Bcr-Abl inhibitors by using combinational strategies of bioisosteric replacement, scaffold hopping, and conformational constraint. The compounds displayed significant inhibition against a broad spectrum of Bcr-Abl mutants including the gatekeeper T315I and p-loop mutations, which are associated with disease progression in CML. The most potent compounds 6q and 6qo strongly inhibited the kinase activities of Bcr-AblWT and Bcr-AblT315I with IC50 values of 0.60, 0.36 and 1.12, 0.98 nM, respectively. They also potently suppressed the proliferation of K562, KU812 human CML cells, and a panel of murine Ba/F3 cells ectopically expressing either Bcr-AblWT or any of a panel of other Bcr-Abl mutants that have been shown to contribute to clinical acquired resistance, including Bcr-AblT315I, with IC50 values in low nanomolar ranges. These compounds may serve as lead compounds for further development of new Bcr-Abl inhibitors capable of overcoming clinical acquired resistance against imatinib.
AB - A series of 3-(1H-1,2,3-triazol-1-yl)benzamide derivatives were designed and synthesized as new Bcr-Abl inhibitors by using combinational strategies of bioisosteric replacement, scaffold hopping, and conformational constraint. The compounds displayed significant inhibition against a broad spectrum of Bcr-Abl mutants including the gatekeeper T315I and p-loop mutations, which are associated with disease progression in CML. The most potent compounds 6q and 6qo strongly inhibited the kinase activities of Bcr-AblWT and Bcr-AblT315I with IC50 values of 0.60, 0.36 and 1.12, 0.98 nM, respectively. They also potently suppressed the proliferation of K562, KU812 human CML cells, and a panel of murine Ba/F3 cells ectopically expressing either Bcr-AblWT or any of a panel of other Bcr-Abl mutants that have been shown to contribute to clinical acquired resistance, including Bcr-AblT315I, with IC50 values in low nanomolar ranges. These compounds may serve as lead compounds for further development of new Bcr-Abl inhibitors capable of overcoming clinical acquired resistance against imatinib.
UR - http://www.scopus.com/inward/record.url?scp=84870003659&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84870003659&partnerID=8YFLogxK
U2 - 10.1021/jm301188x
DO - 10.1021/jm301188x
M3 - Article
C2 - 23088644
AN - SCOPUS:84870003659
SN - 0022-2623
VL - 55
SP - 10033
EP - 10046
JO - Journal of medicinal chemistry
JF - Journal of medicinal chemistry
IS - 22
ER -